MA42527A - Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation - Google Patents
Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisationInfo
- Publication number
- MA42527A MA42527A MA042527A MA42527A MA42527A MA 42527 A MA42527 A MA 42527A MA 042527 A MA042527 A MA 042527A MA 42527 A MA42527 A MA 42527A MA 42527 A MA42527 A MA 42527A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- methods
- receptor agonists
- ht2c receptor
- ht2c
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199382P | 2015-07-31 | 2015-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42527A true MA42527A (fr) | 2021-04-07 |
Family
ID=56684262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042527A MA42527A (fr) | 2015-07-31 | 2016-07-28 | Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10272094B2 (fr) |
| EP (1) | EP3328835B1 (fr) |
| JP (1) | JP6789578B2 (fr) |
| KR (1) | KR20180031035A (fr) |
| CN (1) | CN108137508B (fr) |
| AU (1) | AU2016302755B2 (fr) |
| BR (1) | BR112018001707A2 (fr) |
| CA (1) | CA3002525A1 (fr) |
| EA (1) | EA039412B1 (fr) |
| HK (1) | HK1255850A1 (fr) |
| IL (1) | IL257107B (fr) |
| MA (1) | MA42527A (fr) |
| MX (1) | MX375045B (fr) |
| WO (1) | WO2017023679A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6789578B2 (ja) * | 2015-07-31 | 2020-11-25 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 5−ht2c受容体アゴニストおよび組成物、ならびに使用方法 |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| WO2019131902A1 (fr) | 2017-12-27 | 2019-07-04 | 武田薬品工業株式会社 | Agent thérapeutique pour incontinence urinaire de stress et incontinence fécale |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN110668951B (zh) * | 2018-12-21 | 2022-09-30 | 安徽贝克生物制药有限公司 | 一种盐酸司来吉兰的合成工艺 |
| CN110642721B (zh) * | 2018-12-21 | 2022-09-30 | 安徽贝克生物制药有限公司 | 盐酸司来吉兰的制备方法 |
| KR20220008824A (ko) | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| US20220410894A1 (en) * | 2021-06-29 | 2022-12-29 | Tusimple, Inc. | Systems and methods for operating an autonomous vehicle |
| US12227206B2 (en) | 2021-10-14 | 2025-02-18 | Tusimple, Inc. | Systems and methods for operating an autonomous vehicle |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5180733A (en) * | 1990-03-30 | 1993-01-19 | Abbott Laboratories | Biogenic amine uptake inhibitors |
| AU1919592A (en) | 1991-04-16 | 1992-11-17 | National Institutes Of Health | Method of treating trichotillomania and onychophagia |
| AU2003228485A1 (en) | 2002-04-12 | 2003-10-27 | The University Of Chicago | Farnesoid x-activated receptor agonists |
| US6953787B2 (en) * | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| TW200307682A (en) * | 2002-04-25 | 2003-12-16 | Wyeth Corp | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
| CN1805938B (zh) * | 2003-06-17 | 2010-06-16 | 艾尼纳制药公司 | 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物 |
| WO2005037796A1 (fr) * | 2003-10-08 | 2005-04-28 | Eli Lilly And Company | Composes et techniques de traitement de la dyslipidemie |
| WO2011071136A1 (fr) * | 2009-12-11 | 2011-06-16 | アステラス製薬株式会社 | Agent thérapeutique pour la fibromyalgie |
| EP2824106B1 (fr) * | 2012-03-06 | 2016-11-23 | Takeda Pharmaceutical Company Limited | Composé tricyclique |
| BR112015005743A2 (pt) * | 2012-09-14 | 2017-07-04 | Abbvie Deutschland | derivados tricíclicos de quinoxalina e quinolina |
| JP6789578B2 (ja) | 2015-07-31 | 2020-11-25 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 5−ht2c受容体アゴニストおよび組成物、ならびに使用方法 |
-
2016
- 2016-07-28 JP JP2018504658A patent/JP6789578B2/ja not_active Expired - Fee Related
- 2016-07-28 EP EP16751083.3A patent/EP3328835B1/fr active Active
- 2016-07-28 MA MA042527A patent/MA42527A/fr unknown
- 2016-07-28 WO PCT/US2016/044426 patent/WO2017023679A1/fr not_active Ceased
- 2016-07-28 EA EA201890402A patent/EA039412B1/ru unknown
- 2016-07-28 CN CN201680058247.6A patent/CN108137508B/zh not_active Expired - Fee Related
- 2016-07-28 CA CA3002525A patent/CA3002525A1/fr not_active Abandoned
- 2016-07-28 US US15/748,205 patent/US10272094B2/en active Active
- 2016-07-28 HK HK18114926.0A patent/HK1255850A1/zh unknown
- 2016-07-28 KR KR1020187005698A patent/KR20180031035A/ko not_active Withdrawn
- 2016-07-28 BR BR112018001707A patent/BR112018001707A2/pt active Search and Examination
- 2016-07-28 MX MX2018001380A patent/MX375045B/es active IP Right Grant
- 2016-07-28 AU AU2016302755A patent/AU2016302755B2/en not_active Ceased
-
2018
- 2018-01-23 IL IL257107A patent/IL257107B/en active IP Right Grant
-
2019
- 2019-03-12 US US16/299,880 patent/US10624900B2/en active Active
-
2020
- 2020-04-14 US US16/848,013 patent/US11395824B2/en active Active
-
2022
- 2022-06-10 US US17/837,622 patent/US20230055376A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ739883A (en) | 2021-03-26 |
| US10272094B2 (en) | 2019-04-30 |
| US20200078368A1 (en) | 2020-03-12 |
| CN108137508A (zh) | 2018-06-08 |
| EA201890402A1 (ru) | 2018-09-28 |
| BR112018001707A2 (pt) | 2018-09-18 |
| US20180214455A1 (en) | 2018-08-02 |
| MX2018001380A (es) | 2018-06-15 |
| KR20180031035A (ko) | 2018-03-27 |
| JP6789578B2 (ja) | 2020-11-25 |
| IL257107A (en) | 2018-03-29 |
| US20230055376A1 (en) | 2023-02-23 |
| US20200383993A1 (en) | 2020-12-10 |
| HK1255850A1 (zh) | 2019-08-30 |
| EA039412B1 (ru) | 2022-01-25 |
| WO2017023679A1 (fr) | 2017-02-09 |
| CA3002525A1 (fr) | 2017-02-09 |
| CN108137508B (zh) | 2021-08-27 |
| AU2016302755A1 (en) | 2018-03-15 |
| EP3328835A1 (fr) | 2018-06-06 |
| JP2018522025A (ja) | 2018-08-09 |
| MX375045B (es) | 2025-03-06 |
| IL257107B (en) | 2021-03-25 |
| AU2016302755B2 (en) | 2020-09-10 |
| US11395824B2 (en) | 2022-07-26 |
| US10624900B2 (en) | 2020-04-21 |
| EP3328835B1 (fr) | 2022-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3704239A4 (fr) | Compositions de casz et procédés d'utilisation | |
| EP3600318A4 (fr) | Procédés d'utilisation d'inhibiteurs d'ehmt2 | |
| EP3359523A4 (fr) | Compositions d'oligonucléotides et procédés associés | |
| EP3325017A4 (fr) | Compositions d'oligonucléotides et procédés associés | |
| IL255171A0 (en) | 5-Hydroxytryptamine 2-C receptor agonists. and preparations and methods of use | |
| EP3352774A4 (fr) | Compositions de flavonoïdes et procédés d'utilisation | |
| MA41613A (fr) | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs | |
| EP3373906A4 (fr) | Compositions et procédés destinés à une application sur la peau | |
| EP3621660A4 (fr) | Compositions et procédés d'utilisation de capsides arc | |
| MA40921A (fr) | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation | |
| MA43380A (fr) | Récepteurs chimériques modifiés et compositions et procédés associés | |
| EP3414321A4 (fr) | Compositions améliorant vcn et procédés d'utilisation desdites compositions | |
| EP3688011A4 (fr) | Compositions peptidiques et procédés d'utilisation de ces compositions | |
| EP3394065A4 (fr) | Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés | |
| EP3303435A4 (fr) | Hydrofluoroléfines et procédés d'utilisation associés | |
| EP3384274A4 (fr) | Dispositifs et procédés de caracterisation d'échantillon | |
| EP3316894A4 (fr) | Composés et compositions comprenant des oligodésoxynucléotides phosphorothioés, et procédés d'utilisation associés | |
| EP3386927A4 (fr) | Compositions polymères et procédés d'utilisation | |
| MA50636A (fr) | Compositions et procédés pour inhiber l'activité d'arginase | |
| EP3478277A4 (fr) | Compositions anti-acné et procédés d'utilisation | |
| EP3289064A4 (fr) | Compositions et procédés pour la détection d'allergènes | |
| EP3302558A4 (fr) | Agents anticancéreux et procédés d'utilisation | |
| EP3373950A4 (fr) | Procédés et compositions d'évaluation de spécificités d'anticorps | |
| MA52098A (fr) | Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation | |
| IL257107B (en) | 5-H-T2-C receptor agonists and preparations and methods of use |